Stay updated on XMT-1660 in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the XMT-1660 in Solid Tumors Clinical Trial page.

Latest updates to the XMT-1660 in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedAdded UCLA David Geffen School of Medicine, Division of Hematology/Oncology and Sarah Cannon Research Institute (SCRI) with investigator Jennifer Specht, MD. Removed UCLA and Tennessee Oncology, PLLC and Natasha Hunter, MD.SummaryDifference0.3%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0; no visible changes to the study details page.SummaryDifference0.0%

- Check44 days agoChange Detected- Revision: v3.4.3 added.\n- Revision: v3.4.2 removed.\n- No changes to study data or page content.SummaryDifference0.0%

- Check65 days agoChange DetectedFallopian Tube Cancer has been added to the study's listed conditions. The page revision updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check73 days agoChange DetectedA minor revision label on the page updated from v3.4.0 to v3.4.1; no trial information changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check87 days agoChange DetectedUI updates include Show glossary / Hide glossary and revised QC-related labels (Last Update Submitted that Met QC Criteria, Last Update Posted). There is also a version change to Revision: v3.4.0.SummaryDifference0.3%

Stay in the know with updates to XMT-1660 in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1660 in Solid Tumors Clinical Trial page.